Results of intravitreal dexamethasone implant in the treatment of macular edema secondary to non-infectious uveitis

Session Details

Session Title: Presented Poster Session: News on Phaco

Session Date/Time: Tuesday 08/09/2015 | 09:30-11:00

Paper Time: 10:30

Venue: Poster Village: Pod 4

First Author: : S.Guven Yilmaz TURKEY

Co Author(s): :    F. Afrashi   Z. Oztas   H. Ates        

Abstract Details

Purpose:

To report our experience with dexamethasone intravitreal implant in patients with macular edema secondary to non-infectious uveitis.

Setting:

Ege University, School of Medicine, Department of Ophthalmology

Methods:

A retrospective chart review of 15 eyes of 12 (5 male and 7 female) consecutive patients with macular edema due to non-infectious uveitis treated with 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA) was performed. Complete ophthalmic examination including best corrected visual acuity (BCVA), central macular thickness (CMT) measurement (obtained by spectral domain optical coherence tomography), and intraocular pressure (IOP ) were assessed before and 1 week, 1, 3 and 6 months after injection.

Results:

The mean age of the patients was 44.2±23.0 years and mean follow-up was 11.7±7.6 months. The baseline CMT (559.80±176.75μm) improved to 395.20±139.36μm, 315.33±107.86μm, and 311.66±97.67μm in week 1, month 1 and 3, respectively (p values less than 0.05). The mean CMT returned back to pre-injection value (545.55±163.14μm) at 6 month. Pre-injection BCVA (1.1 logMAR units) improved to 0.8 and 0.6 at month 1 and 3, respectively, to finally reach 0.9 logMAR units in month 6. Increment of IOP (higher than 21mmHg) occurred within the first month in 3 (20%) eyes; two eyes were effectively managed with topical hypotensive medications, while glaucoma surgery was needed in one eye.

Conclusions:

Dexamethasone 0.7 mg intravitreal implant produced improvements in both visual acuity and retinal thickness from the first week and this improvements were sustained until the third month. Because of gradually recurrence of macular edema in most eyes and risk of IOP elevation, close post treatment monitoring is recommended.

Financial Interest:

NONE